R 2487
Alternative Names: R-2487; R-2487 DPLatest Information Update: 09 Jun 2026
At a glance
- Originator Rise Therapeutics
- Class Antirheumatics; Bacteria; Gene therapies; Immunotherapies; Probiotics
- Mechanism of Action Bacteria replacements; Colonisation factor antigen expression stimulants; Regulatory T-lymphocyte modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Rheumatoid arthritis
- Clinical Phase Unknown Sjogren's syndrome
Most Recent Events
- 02 Jun 2026 Phase-I clinical trials in Rheumatoid arthritis (Combination therapy) in USA (PO) prior to June 2026 (NCT05961592)
- 02 Jun 2026 Rise Therapeutics plans a phase II trial for Rheumatoid arthritis
- 28 Jan 2026 US FDA approves IND application for R 2487 in Sjogren's syndrome (Rise Therapeutics pipeline, January 2026)